{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:26:30Z","timestamp":1782199590768,"version":"3.54.5"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10741-021-10180-z","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:04:49Z","timestamp":1637053489000},"page":"1587-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted treatments of AL and ATTR amyloidosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Pranav","family":"Chandrashekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry H.","family":"Trachtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"10180_CR1","doi-asserted-by":"publisher","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","volume":"7","author":"E Imperlini","year":"2017","unstructured":"Imperlini E, Gnecchi M, Rognoni P et al (2017) Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep 7:15661. https:\/\/doi.org\/10.1038\/s41598-017-15424-3","journal-title":"Sci Rep"},{"key":"10180_CR2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20140155","volume":"35","author":"P Manral","year":"2015","unstructured":"Manral P, Reixach N (2015) Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci Rep 35:e00172. https:\/\/doi.org\/10.1042\/BSR20140155","journal-title":"Biosci Rep"},{"key":"10180_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA (2011) Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29:1924\u20131933. https:\/\/doi.org\/10.1200\/JCO.2010.32.2271","journal-title":"J Clin Oncol"},{"key":"10180_CR4","doi-asserted-by":"publisher","first-page":"15525","DOI":"10.1021\/bi051608t","volume":"44","author":"TR Foss","year":"2005","unstructured":"Foss TR, Wiseman RL, Kelly JW (2005) The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44:15525\u201315533. https:\/\/doi.org\/10.1021\/bi051608t","journal-title":"Biochemistry"},{"key":"10180_CR5","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","volume":"249","author":"Y Kanda","year":"1974","unstructured":"Kanda Y, Goodman DS, Canfield RE, Morgan FJ (1974) The amino acid sequence of human plasma prealbumin. J Biol Chem 249:6796\u20136805","journal-title":"J Biol Chem"},{"key":"10180_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","volume":"121","author":"Y Sekijima","year":"2005","unstructured":"Sekijima Y, Wiseman RL, Matteson J et al (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73\u201385. https:\/\/doi.org\/10.1016\/j.cell.2005.01.018","journal-title":"Cell"},{"key":"10180_CR7","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao L, Buxbaum JN, Reixach N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52:1913\u20131926. https:\/\/doi.org\/10.1021\/bi301313b","journal-title":"Biochemistry"},{"key":"10180_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Witztum JL, Bennett CF, Baker BF (2018) RNA-Targeted Therapeutics. Cell Metab 27:714\u2013739. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.004","journal-title":"Cell Metab"},{"key":"10180_CR9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC et al (2018) A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22:2227\u20132235. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.014","journal-title":"Cell Rep"},{"key":"10180_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"10180_CR11","unstructured":"US FDA (2018) Drug Approval Package: Tegsedi (inotersen). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211172Orig1s000TOC.cfm"},{"key":"10180_CR12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"10180_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/cb501028c","volume":"10","author":"S Matsuda","year":"2015","unstructured":"Matsuda S, Keiser K, Nair JK et al (2015) siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol 10:1181\u20131187. https:\/\/doi.org\/10.1021\/cb501028c","journal-title":"ACS Chem Biol"},{"key":"10180_CR14","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1093\/nar\/gkx960","volume":"45","author":"M Tanowitz","year":"2017","unstructured":"Tanowitz M, Hettrick L, Revenko A, Kinberger GA, Prakash TP, Seth PP (2017) Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res 45:12388\u201312400. https:\/\/doi.org\/10.1093\/nar\/gkx960","journal-title":"Nucleic Acids Res"},{"key":"10180_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ et al (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8:652\u2013661. https:\/\/doi.org\/10.1002\/ehf2.13154","journal-title":"ESC Heart Fail"},{"key":"10180_CR16","unstructured":"U.S. National Library of Medicine (2019) NEURO-TTRansform: A study to evaluate the efficacy and safety of AKCEA-TTR-LRx in participants with hereditary transthyretin-mediated amyloid polyneuropathy. https:\/\/ClinicalTrials.gov\/show\/NCT04136184"},{"key":"10180_CR17","unstructured":"U.S. National Library of Medicine (2019) CARDIO-TTRansform: A study to evaluate the efficacy and safety of AKCEA-TTR-LRx in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). https:\/\/ClinicalTrials.gov\/show\/NCT04136171"},{"key":"10180_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1248\/bpb.b18-00625","volume":"41","author":"Y Hayashi","year":"2018","unstructured":"Hayashi Y, Jono H (2018) Recent advances in oligonucleotide-based therapy for transthyretin amyloidosis: clinical impact and future prospects. Biol Pharm Bull 41:1737\u20131744. https:\/\/doi.org\/10.1248\/bpb.b18-00625","journal-title":"Biol Pharm Bull"},{"key":"10180_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811. https:\/\/doi.org\/10.1038\/35888","journal-title":"Nature"},{"key":"10180_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1208760","journal-title":"N Engl J Med"},{"key":"10180_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J et al (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109. https:\/\/doi.org\/10.1186\/s13023-015-0326-6","journal-title":"Orphanet J Rare Dis"},{"key":"10180_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"10180_CR23","unstructured":"U.S. National Library of Medicine (2019) APOLLO-B: A study to evaluate patisiran in participants with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). https:\/\/ClinicalTrials.gov\/show\/NCT03997383"},{"key":"10180_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H et al (2021) Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther 109:372\u2013382. https:\/\/doi.org\/10.1002\/cpt.1974","journal-title":"Clin Pharmacol Ther"},{"key":"10180_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","volume":"34","author":"DP Judge","year":"2020","unstructured":"Judge DP, Kristen AV, Grogan M et al (2020) Phase 3 Multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 34:357\u2013370. https:\/\/doi.org\/10.1007\/s10557-019-06919-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"10180_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas MM, Schlegel MK, Harbison CE et al (2018) Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun 9:723. https:\/\/doi.org\/10.1038\/s41467-018-02989-4","journal-title":"Nat Commun"},{"key":"10180_CR27","unstructured":"U.S. National Library of Medicine (2019) HELIOS-B: A study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. https:\/\/ClinicalTrials.gov\/show\/NCT04153149"},{"key":"10180_CR28","unstructured":"U.S. National Library of Medicine (2018) HELIOS-A: A study of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). https:\/\/ClinicalTrials.gov\/show\/NCT03759379"},{"key":"10180_CR29","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1016\/s0735-1097(20)34206-6","volume":"75","author":"R Shilling","year":"2020","unstructured":"Shilling R, Karsten V, Silliman N, Chen J, Li W, Vest J (2020) Study design and rationale of Helios-B: a phase 3 study to evaluate the clinical efficacy and safety of vutrisiran in patients with Attr amyloidosis with cardiomyopathy. J Am Coll Cardiol 75:3579. https:\/\/doi.org\/10.1016\/s0735-1097(20)34206-6","journal-title":"J Am Coll Cardiol"},{"key":"10180_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339:819\u2013823. https:\/\/doi.org\/10.1126\/science.1231143","journal-title":"Science"},{"key":"10180_CR31","unstructured":"U.S. National Library of Medicine (2020) Study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). https:\/\/ClinicalTrials.gov\/show\/NCT04601051"},{"key":"10180_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.05.010","author":"J Wen","year":"2021","unstructured":"Wen J, Cao T, Wu J et al (2021) Single AAV-mediated CRISPR\/Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.010","journal-title":"Mol Ther"},{"key":"10180_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 21:282\u2013292. https:\/\/doi.org\/10.1002\/lt.24058","journal-title":"Liver Transpl"},{"key":"10180_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","volume":"78","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Ando Y, Okamoto S et al (2012) Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78:637\u2013643. https:\/\/doi.org\/10.1212\/WNL.0b013e318248df18","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10180_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2011.574354064","volume":"18","author":"S Okamoto","year":"2011","unstructured":"Okamoto S, Wixner J, Ericzon BG et al (2011) Prognostic value of pre-transplant cardiomyopathy in Swedish liver transplanted patients for familial amyloidotic polyneuropathy. Amyloid 18(Suppl 1):171\u2013173. https:\/\/doi.org\/10.3109\/13506129.2011.574354064","journal-title":"Amyloid"},{"key":"10180_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL et al (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31. https:\/\/doi.org\/10.1186\/1750-1172-8-31","journal-title":"Orphanet J Rare Dis"},{"key":"10180_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/TP.0b013e31824b3749","volume":"93","author":"S Gustafsson","year":"2012","unstructured":"Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB (2012) Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 93:1017\u20131023. https:\/\/doi.org\/10.1097\/TP.0b013e31824b3749","journal-title":"Transplantation"},{"key":"10180_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0022-510x(99)00231-2","volume":"171","author":"K Tashima","year":"1999","unstructured":"Tashima K, Ando Y, Terazaki H et al (1999) Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 171:19\u201323. https:\/\/doi.org\/10.1016\/s0022-510x(99)00231-2","journal-title":"J Neurol Sci"},{"key":"10180_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-m","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G, Ericzon BG, Groth CG et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113\u20131116. https:\/\/doi.org\/10.1016\/0140-6736(93)93127-m","journal-title":"Lancet"},{"key":"10180_CR40","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2169\/internalmedicine.47.1399","volume":"47","author":"S Okamoto","year":"2008","unstructured":"Okamoto S, Yamashita T, Ando Y et al (2008) Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med 47:2133\u20132137. https:\/\/doi.org\/10.2169\/internalmedicine.47.1399","journal-title":"Intern Med"},{"key":"10180_CR41","doi-asserted-by":"publisher","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","volume":"115","author":"L Saelices","year":"2018","unstructured":"Saelices L, Chung K, Lee JH et al (2018) Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc Natl Acad Sci USA 115:E6741\u2013E6750. https:\/\/doi.org\/10.1073\/pnas.1805131115","journal-title":"Proc Natl Acad Sci USA"},{"key":"10180_CR42","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/lt.22174","volume":"16","author":"L Llado","year":"2010","unstructured":"Llado L, Baliellas C, Casasnovas C et al (2010) Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 16:1386\u20131392. https:\/\/doi.org\/10.1002\/lt.22174","journal-title":"Liver Transpl"},{"key":"10180_CR43","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1056\/NEJM200506023522219","volume":"352","author":"AJ Stangou","year":"2005","unstructured":"Stangou AJ, Heaton ND, Hawkins PN (2005) Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 352:2356. https:\/\/doi.org\/10.1056\/NEJM200506023522219","journal-title":"N Engl J Med"},{"key":"10180_CR44","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1021\/bi00151a036","volume":"31","author":"W Colon","year":"1992","unstructured":"Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31:8654\u20138660. https:\/\/doi.org\/10.1021\/bi00151a036","journal-title":"Biochemistry"},{"key":"10180_CR45","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","volume":"93","author":"GJ Miroy","year":"1996","unstructured":"Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 93:15051\u201315056. https:\/\/doi.org\/10.1073\/pnas.93.26.15051","journal-title":"Proc Natl Acad Sci USA"},{"key":"10180_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2174\/156800705774322076","volume":"4","author":"MR Almeida","year":"2005","unstructured":"Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ (2005) Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 4:587\u2013596. https:\/\/doi.org\/10.2174\/156800705774322076","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10180_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/labinvest.3700059","volume":"84","author":"SR Miller","year":"2004","unstructured":"Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84:545\u2013552. https:\/\/doi.org\/10.1038\/labinvest.3700059","journal-title":"Lab Invest"},{"key":"10180_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13:236\u2013249. https:\/\/doi.org\/10.1080\/13506120600960882","journal-title":"Amyloid"},{"key":"10180_CR49","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658\u20132667. https:\/\/doi.org\/10.1001\/jama.2013.283815","journal-title":"JAMA"},{"key":"10180_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","volume":"18","author":"A Castano","year":"2012","unstructured":"Castano A, Helmke S, Alvarez J, Delisle S, Maurer MS (2012) Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 18:315\u2013319. https:\/\/doi.org\/10.1111\/j.1751-7133.2012.00303.x","journal-title":"Congest Heart Fail"},{"key":"10180_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.117.004769","volume":"11","author":"H Rosenblum","year":"2018","unstructured":"Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS (2018) TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis. Circ Heart Fail 11:e004769. https:\/\/doi.org\/10.1161\/circheartfailure.117.004769","journal-title":"Circ Heart Fail"},{"key":"10180_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","volume":"25","author":"A Ikram","year":"2018","unstructured":"Ikram A, Donnelly JP, Sperry BW, Samaras C, Valent J, Hanna M (2018) Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center\u2019s experience. Amyloid 25:197\u2013202. https:\/\/doi.org\/10.1080\/13506129.2018.1519507","journal-title":"Amyloid"},{"key":"10180_CR53","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R et al (2020) Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail 26:753\u2013759. https:\/\/doi.org\/10.1016\/j.cardfail.2019.11.024","journal-title":"J Card Fail"},{"key":"10180_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE et al (2016) Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 5:1\u201325. https:\/\/doi.org\/10.1007\/s40120-016-0040-x","journal-title":"Neurol Ther"},{"key":"10180_CR55","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10180_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40256-020-00461-7","volume":"21","author":"YN Lamb","year":"2021","unstructured":"Lamb YN (2021) Tafamidis: a review in transthyretin amyloid cardiomyopathy. Am J Cardiovasc Drugs 21:113\u2013121. https:\/\/doi.org\/10.1007\/s40256-020-00461-7","journal-title":"Am J Cardiovasc Drugs"},{"key":"10180_CR57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M et al (2021) Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 23:277\u2013285. https:\/\/doi.org\/10.1002\/ejhf.2027","journal-title":"Eur J Heart Fail"},{"key":"10180_CR58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","volume":"5","author":"JH Gurwitz","year":"2020","unstructured":"Gurwitz JH, Maurer MS (2020) Tafamidis\u2014A pricey therapy for a not-so-rare condition. JAMA Cardiol 5:247\u2013248. https:\/\/doi.org\/10.1001\/jamacardio.2019.5233","journal-title":"JAMA Cardiol"},{"key":"10180_CR59","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/circulationaha.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ et al (2020) Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 141:1214\u20131224. https:\/\/doi.org\/10.1161\/circulationaha.119.045093","journal-title":"Circulation"},{"key":"10180_CR60","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","volume":"5","author":"A Masri","year":"2020","unstructured":"Masri A, Chen H, Wong C et al (2020) Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history. JAMA Cardiol 5:1066\u20131067. https:\/\/doi.org\/10.1001\/jamacardio.2020.1738","journal-title":"JAMA Cardiol"},{"key":"10180_CR61","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC, Connelly S, Wang Y et al (2013) AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA 110:9992\u20139997. https:\/\/doi.org\/10.1073\/pnas.1300761110","journal-title":"Proc Natl Acad Sci USA"},{"key":"10180_CR62","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1126\/science.1062245","volume":"293","author":"P Hammarstrom","year":"2001","unstructured":"Hammarstrom P, Schneider F, Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science 293:2459\u20132462. https:\/\/doi.org\/10.1126\/science.1062245","journal-title":"Science"},{"key":"10180_CR63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1210\/jcem.77.2.8102146","volume":"77","author":"IL Alves","year":"1993","unstructured":"Alves IL, Divino CM, Schussler GC et al (1993) Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab 77:484\u2013488. https:\/\/doi.org\/10.1210\/jcem.77.2.8102146","journal-title":"J Clin Endocrinol Metab"},{"key":"10180_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH et al (2019) Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 74:285\u2013295. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.012","journal-title":"J Am Coll Cardiol"},{"key":"10180_CR65","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","volume":"7","author":"R Sant'Anna","year":"2016","unstructured":"Sant\u2019Anna R, Gallego P, Robinson LZ et al (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 7:10787. https:\/\/doi.org\/10.1038\/ncomms10787","journal-title":"Nat Commun"},{"key":"10180_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41598-017-00338-x","volume":"7","author":"G Verona","year":"2017","unstructured":"Verona G, Mangione PP, Raimondi S et al (2017) Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Sci Rep 7:182. https:\/\/doi.org\/10.1038\/s41598-017-00338-x","journal-title":"Sci Rep"},{"key":"10180_CR67","doi-asserted-by":"publisher","first-page":"20483","DOI":"10.1073\/pnas.1008255107","volume":"107","author":"SE Kolstoe","year":"2010","unstructured":"Kolstoe SE, Mangione PP, Bellotti V et al (2010) Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA 107:20483\u201320488. https:\/\/doi.org\/10.1073\/pnas.1008255107","journal-title":"Proc Natl Acad Sci USA"},{"key":"10180_CR68","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1021\/acs.jmedchem.9b01037","volume":"62","author":"A Corazza","year":"2019","unstructured":"Corazza A, Verona G, Waudby CA et al (2019) Binding of monovalent and bivalent ligands by transthyretin causes different short- and long-distance conformational changes. J Med Chem 62:8274\u20138283. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01037","journal-title":"J Med Chem"},{"key":"10180_CR69","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814. https:\/\/doi.org\/10.1007\/s00415-013-7051-7","journal-title":"J Neurol"},{"key":"10180_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","volume":"2017","author":"G Merlini","year":"2017","unstructured":"Merlini G (2017) AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program 2017:1\u201312. https:\/\/doi.org\/10.1182\/asheducation-2017.1.1","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10180_CR71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","volume":"82","author":"LM Blancas-Mejia","year":"2013","unstructured":"Blancas-Mejia LM, Ramirez-Alvarado M (2013) Systemic amyloidoses. Annu Rev Biochem 82:745\u2013774. https:\/\/doi.org\/10.1146\/annurev-biochem-072611-130030","journal-title":"Annu Rev Biochem"},{"key":"10180_CR72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1006\/jsbi.2000.4248","volume":"130","author":"V Bellotti","year":"2000","unstructured":"Bellotti V, Mangione P, Merlini G (2000) Review: immunoglobulin light chain amyloidosis\u2013the archetype of structural and pathogenic variability. J Struct Biol 130:280\u2013289. https:\/\/doi.org\/10.1006\/jsbi.2000.4248","journal-title":"J Struct Biol"},{"key":"10180_CR73","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128:1554\u20131575. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187","journal-title":"Circ Res"},{"key":"10180_CR74","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"10180_CR75","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"10180_CR76","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK et al (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129:2111\u20132119. https:\/\/doi.org\/10.1182\/blood-2016-11-751628","journal-title":"Blood"},{"key":"10180_CR77","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G et al (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26:2317\u20132325. https:\/\/doi.org\/10.1038\/leu.2012.100","journal-title":"Leukemia"},{"key":"10180_CR78","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","volume":"96","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Gertz MA et al (2021) Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc 96:1546\u20131577. https:\/\/doi.org\/10.1016\/j.mayocp.2021.03.012","journal-title":"Mayo Clin Proc"},{"key":"10180_CR79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/nejm199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 335:91\u201397. https:\/\/doi.org\/10.1056\/nejm199607113350204","journal-title":"N Engl J Med"},{"key":"10180_CR80","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med"},{"key":"10180_CR81","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, Moreau P, Leblond V et al (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083\u20131093. https:\/\/doi.org\/10.1056\/NEJMoa070484","journal-title":"N Engl J Med"},{"key":"10180_CR82","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","volume":"103","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ et al (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103:3960\u20133963. https:\/\/doi.org\/10.1182\/blood-2003-12-4192","journal-title":"Blood"},{"key":"10180_CR83","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16096","volume":"187","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Lacy MQ et al (2019) Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol 187:588\u2013594. https:\/\/doi.org\/10.1111\/bjh.16096","journal-title":"Br J Haematol"},{"key":"10180_CR84","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ajh.24453","volume":"91","author":"YL Hwa","year":"2016","unstructured":"Hwa YL, Kumar SK, Gertz MA et al (2016) Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol 91:984\u2013988. https:\/\/doi.org\/10.1002\/ajh.24453","journal-title":"Am J Hematol"},{"key":"10180_CR85","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93:1169\u20131180. https:\/\/doi.org\/10.1002\/ajh.25149","journal-title":"Am J Hematol"},{"key":"10180_CR86","unstructured":"U.S. National Library of Medicine (2021) A Study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to CyBorD alone in newly diagnosed systemic amyloid light-chain (AL) amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT03201965"},{"key":"10180_CR87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","volume":"11","author":"R Al Hamed","year":"2021","unstructured":"Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M (2021) Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J 11:97. https:\/\/doi.org\/10.1038\/s41408-021-00486-4","journal-title":"Blood Cancer J"},{"key":"10180_CR88","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","volume":"130","author":"GP Kaufman","year":"2017","unstructured":"Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M (2017) Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 130:900\u2013902. https:\/\/doi.org\/10.1182\/blood-2017-01-763599","journal-title":"Blood"},{"key":"10180_CR89","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","volume":"33","author":"JP Abeykoon","year":"2019","unstructured":"Abeykoon JP, Zanwar S, Dispenzieri A et al (2019) Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia 33:531\u2013536. https:\/\/doi.org\/10.1038\/s41375-018-0262-2","journal-title":"Leukemia"},{"key":"10180_CR90","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/156800911794519716","volume":"11","author":"BC Potts","year":"2011","unstructured":"Potts BC, Albitar MX, Anderson KC et al (2011) Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11:254\u2013284. https:\/\/doi.org\/10.2174\/156800911794519716","journal-title":"Curr Cancer Drug Targets"},{"key":"10180_CR91","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","volume":"33","author":"T Bochtler","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C et al (2015) Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 33:1371\u20131378. https:\/\/doi.org\/10.1200\/JCO.2014.57.4947","journal-title":"J Clin Oncol"},{"key":"10180_CR92","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B et al (2020) Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 38:3252\u20133260. https:\/\/doi.org\/10.1200\/JCO.20.01285","journal-title":"J Clin Oncol"},{"key":"10180_CR93","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini G, Milani P, Foli A et al (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 99:743\u2013750. https:\/\/doi.org\/10.3324\/haematol.2013.095463","journal-title":"Haematologica"},{"key":"10180_CR94","first-page":"1681","volume":"8","author":"S Greenstein","year":"2002","unstructured":"Greenstein S, Ghias K, Krett NL, Rosen ST (2002) Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 8:1681\u20131694","journal-title":"Clin Cancer Res"},{"key":"10180_CR95","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/ndt\/gfq482","volume":"26","author":"R Specter","year":"2011","unstructured":"Specter R, Sanchorawala V, Seldin DC et al (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 26:881\u2013886. https:\/\/doi.org\/10.1093\/ndt\/gfq482","journal-title":"Nephrol Dial Transplant"},{"key":"10180_CR96","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","volume":"119","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Buadi F, Laumann K et al (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119:5397\u20135404. https:\/\/doi.org\/10.1182\/blood-2012-02-413161","journal-title":"Blood"},{"key":"10180_CR97","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","volume":"129","author":"G Palladini","year":"2017","unstructured":"Palladini G, Milani P, Foli A et al (2017) A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood 129:2120\u20132123. https:\/\/doi.org\/10.1182\/blood-2016-12-756528","journal-title":"Blood"},{"key":"10180_CR98","doi-asserted-by":"publisher","first-page":"8546","DOI":"10.1200\/JCO.2020.38.15_suppl.8546","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Dispenzieri A, Wechalekar AD et al (2020) Ixazomib-dexamethasone (Ixa-Dex) vs physician\u2019s choice (PC) in relapsed\/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. J Clin Oncol 38:8546. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8546","journal-title":"J Clin Oncol"},{"key":"10180_CR99","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjh.16122","volume":"187","author":"R Manwani","year":"2019","unstructured":"Manwani R, Mahmood S, Sachchithanantham S et al (2019) Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol 187:638\u2013641. https:\/\/doi.org\/10.1111\/bjh.16122","journal-title":"Br J Haematol"},{"key":"10180_CR100","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630\u20131642. https:\/\/doi.org\/10.1016\/S1470-2045(20)30525-8","journal-title":"Lancet Oncol"},{"key":"10180_CR101","unstructured":"U.S. National Library of Medicine (2016) Trial of venetoclax (ABT-199) and dexamethasone for relapsed or refractory systemic AL amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT03000660"},{"key":"10180_CR102","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","volume":"10","author":"MH Sidiqi","year":"2020","unstructured":"Sidiqi MH, Al Saleh AS, Leung N et al (2020) Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 10:55. https:\/\/doi.org\/10.1038\/s41408-020-0321-6","journal-title":"Blood Cancer J"},{"key":"10180_CR103","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","volume":"8","author":"TG Martin","year":"2019","unstructured":"Martin TG, Corzo K, Chiron M et al (2019) Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells 8:1522. https:\/\/doi.org\/10.3390\/cells8121522","journal-title":"Cells"},{"key":"10180_CR104","unstructured":"U.S. National Library of Medicine (2018) S1702 Isatuximab in treating patients with relapsed or refractory primary amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT03499808"},{"key":"10180_CR105","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"I Cardoso","year":"2010","unstructured":"Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ (2010) Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 8:74. https:\/\/doi.org\/10.1186\/1479-5876-8-74","journal-title":"J Transl Med"},{"key":"10180_CR106","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/s0014-5793(00)02380-2","volume":"487","author":"G Forloni","year":"2001","unstructured":"Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404\u2013407. https:\/\/doi.org\/10.1016\/s0014-5793(00)02380-2","journal-title":"FEBS Lett"},{"issue":"Suppl 1","key":"10180_CR107","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"L Obici","year":"2012","unstructured":"Obici L, Cortese A, Lozza A et al (2012) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34\u201336. https:\/\/doi.org\/10.3109\/13506129.2012.678508","journal-title":"Amyloid"},{"key":"10180_CR108","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","volume":"24","author":"J Wixner","year":"2017","unstructured":"Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I (2017) Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid 24:78\u201379. https:\/\/doi.org\/10.1080\/13506129.2016.1269739","journal-title":"Amyloid"},{"key":"10180_CR109","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cardfail.2019.01.014","volume":"25","author":"RM Witteles","year":"2019","unstructured":"Witteles RM (2019) Doxycycline and ursodiol for ATTR amyloidosis: not ready for prime time. J Card Fail 25:154\u2013155. https:\/\/doi.org\/10.1016\/j.cardfail.2019.01.014","journal-title":"J Card Fail"},{"key":"10180_CR110","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","volume":"148","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Tennent GA, Hutchinson WL et al (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148:760\u2013767. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08036.x","journal-title":"Br J Haematol"},{"key":"10180_CR111","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jnc.15233","volume":"156","author":"MF Dohrn","year":"2021","unstructured":"Dohrn MF, Ihne S, Hegenbart U et al (2021) Targeting transthyretin - mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. J Neurochem 156:802\u2013818. https:\/\/doi.org\/10.1111\/jnc.15233","journal-title":"J Neurochem"},{"key":"10180_CR112","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC et al (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373:1106\u20131114. https:\/\/doi.org\/10.1056\/NEJMoa1504942","journal-title":"N Engl J Med"},{"key":"10180_CR113","unstructured":"U.S. National Library of Medicine (2019) Multiple treatment session study to assess GSK2398852 administered following and along with GSK2315698. https:\/\/ClinicalTrials.gov\/show\/NCT03044353"},{"key":"10180_CR114","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.1038\/srep25080","volume":"6","author":"NJ Galant","year":"2016","unstructured":"Galant NJ, Bugyei-Twum A, Rakhit R et al (2016) Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep 6:25080. https:\/\/doi.org\/10.1038\/srep25080","journal-title":"Sci Rep"},{"key":"10180_CR115","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","volume":"34","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Landau H, Comenzo RL et al (2016) First-in-human phase I\/II Study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 34:1097\u20131103. https:\/\/doi.org\/10.1200\/JCO.2015.63.6530","journal-title":"J Clin Oncol"},{"key":"10180_CR116","unstructured":"U.S. National Library of Medicine (2019) The PRONTO Study, a global phase 2b study of NEOD001 in previously treated subjects with light chain (AL) amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT02632786"},{"key":"10180_CR117","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-139323","volume":"136","author":"J Valent","year":"2020","unstructured":"Valent J, Silowsky J, Kurman MR et al (2020) Cael-101 is well-tolerated in AL amyloidosis patients receiving concomitant cyclophosphamide-bortezomib-dexamethasone (CyborD): a phase 2 dose-finding study (NCT04304144). Blood 136:26\u201327. https:\/\/doi.org\/10.1182\/blood-2020-139323","journal-title":"Blood"},{"key":"10180_CR118","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki JN, Chakrabartty A, Galant NJ et al (2016) Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 23:86\u201397. https:\/\/doi.org\/10.3109\/13506129.2016.1148025","journal-title":"Amyloid"},{"key":"10180_CR119","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13506129.2017.1293514","volume":"24","author":"Y Ando","year":"2017","unstructured":"Ando Y, Ueda M (2017) Antibody therapy for transthyretin-related hereditary amyloid polyneuropathy: another therapeutic option. Amyloid 24:113\u2013114. https:\/\/doi.org\/10.1080\/13506129.2017.1293514","journal-title":"Amyloid"},{"key":"10180_CR120","unstructured":"U.S. National Library of Medicine (2017) A study of PRX004 in subjects with amyloid transthyretin (ATTR) amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT03336580"},{"key":"10180_CR121","unstructured":"U.S. National Library of Medicine (2020) First-in-human study of NI006 in patients with amyloid transthyretin cardiomyopathy. https:\/\/ClinicalTrials.gov\/show\/NCT04360434"},{"key":"10180_CR122","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/cncr.30051","volume":"122","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A et al (2016) Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer 122:2197\u20132205. https:\/\/doi.org\/10.1002\/cncr.30051","journal-title":"Cancer"},{"key":"10180_CR123","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/13506120209114818","volume":"9","author":"II van Gameren","year":"2002","unstructured":"van Gameren II, Hazenberg BPC, Jager PL, Smit JW, Vellenga E (2002) AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 9:165\u2013174. https:\/\/doi.org\/10.3109\/13506120209114818","journal-title":"Amyloid"},{"key":"10180_CR124","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/13506120412331336907","volume":"11","author":"T Gono","year":"2004","unstructured":"Gono T, Matsuda M, Shimojima Y et al (2004) VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11:245\u2013256. https:\/\/doi.org\/10.1080\/13506120412331336907","journal-title":"Amyloid"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10180-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T07:31:54Z","timestamp":1660807914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10180-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10180"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10180-z","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"12 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pranav Chandrashekar is supported by a nationally competitive educational grant from Pfizer paid directly to OHSU. Barry Trachtenberg is a speaker for Pfizer, Akcea, and Alnylam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}